Among a plethora of therapeutic nuclides, 131I possesses a prolonged half‐life, is appropriate for SPECT diagnosis, and its labeling approach is straightforward, without influencing the structure and activity of antibodies.[38, 39] In our study, the affinity of tinurilimab remained high even after 131I labeling (Kd = 0.3 nm), and 131I‐tinurilimab was progressively and significantly accumulated in CEACAM6‐positive tumor after once administration. The gene discussed is CEACAM6; the disease is neoplasm.